None listed
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Age: = 19 years - Sex: Female - ER- positive/HER2-negative breast cancer patients, who were diagnosed with metastatic recurrence after primary treatment(surgery +/-, radiotherapy, neoadjuvant or adjuvant chemotherapy, adjuvant hormone therapy) for more than one year. - Oligometastases: = 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs) - If the metastatic lesion count is different in patients who have performed two or more imaging test, more will be the result of the suspected imaging. - Metastatic lesions are up to 3 cm or less. - Lung : lesion within one side - Liver: lesion within single lobe - Lymph node : lesion with no more than two metastatic lymph node as mediastinum or opposite axilla, supraclavicular node and neck. Confirmed by a biopsy Two or more imaging test suspect metastasis - Metastatic lesions are feasible for loco-regional therapy (resection, radiotherapy, or radiofrequency ablation) (size=3cm) - Patients who are able to communicate without problems with obtaining consent related to the clinical trial
Exclusion criteria
Exclusion criteria: - Excludes patients who have any of the following criteria: - Multiple metastatis (3 or more metastatic lesions within a single organ, 2 or more metastatic organs) - In case local treatment(resection, radiotherapy, or radiofrequency ablation) is not possible even if there are two or fewer lesions within a organ - Patients with other primary cancer (except thyroid cancer and melanoma) - Pregnancy and lactating women - Unable to read consent form (ex:illiterate, foreigner etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Countries
Korea, Republic of
Contacts
Yonsei University Health System, Gangnam Severance Hospital